European Pharmaceutical Review

MARCH 31, 2023

Following the collapse of Silicon Valley Bank (SVB), HSBC’s acquisition of Silicon Valley Bank (SVP) UK may offer new opportunities for biopharmaceutical companies, according to data and analytics firm, GlobalData. “The The post Biopharma could reap benefits from SVB UK acquisition appeared first on European Pharmaceutical Review.

Biopharma 90

Biopharma Pharma Networking Marketing 90

Pharmaceutical Technology

MARCH 16, 2023

Silicon Valley Bank (SVB), the 16th largest bank in the US, collapsed on Friday 10 March. News of the SVB crisis spread quickly from 8–10 March and into the weekend, and the US government finally announced on 12 March that commercial clients would be able to access all of their funds.

Biopharma 59

Biopharma Insurance Government Pharmaceutical 59

PharmaVoice

MAY 17, 2023

How the CEO starts each day with a ride on one of her horses, reduces daily meetings and uses her network to get through crises like the SVB Bank collapse.

Networking 52

Networking Pharma 52

Zymewire

MARCH 30, 2023

Crisis Averted?

Biopharma 52

Biopharma 52

Pharmaceutical Technology

MAY 22, 2023

The possibility of additional funding comes at a time replete with investor uncertainty as a result of ongoing financial instability in the market, which has been compounded by the collapse of Silicon Valley Bank (SVB) and Credit Suisse. billion ($103 billion) budget. billion ($18.2 billion) by 2030.

Marketing 111

Marketing Government Prospecting Medicine 111

Pharmaceutical Technology

MARCH 15, 2023

The recent collapse on March 10, 2023, of the then-parent company Silicon Valley Bank, was the second largest bank failure in US history. The multinational bank HSBC’s acquisition of Silicon Valley Bank UK was praised as the UK Government and Bank of England moved quickly to secure the deal over the weekend. in deposits. in deposits.

Medicine 59

Medicine Marketing Pharma Government 59

Pharmaceutical Technology

MARCH 21, 2023

The biotech industry is currently undergoing a wider financial upheaval after the collapse of Silicon Valley Bank (SVB) , which was favoured by many biotech companies. In such turbulent times, ensuring the most efficient and cost-effective manufacturing frameworks becomes even more important.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59